Literature DB >> 15249188

Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning.

Derek J Hausenloy1, Mihaela M Mocanu, Derek M Yellon.   

Abstract

OBJECTIVES: Recruitment of the survival kinase cascades, PI3K-Akt and Raf-MEK1/2-Erk1/2, at the time of reperfusion, following a lethal ischemic insult, may mediate the protection associated with ischemic preconditioning (IPC). The exact interplay between these two kinase cascades in mediating this effect is not clear. We examine the 'cross-talk' between these kinase cascades in their contribution to IPC-induced protection. METHODS AND
RESULTS: In isolated perfused rat hearts subjected to 35 min of lethal ischemia +/- ischemic preconditioning, the phosphorylation states of Akt, Erk1/2, p70S6K were determined after 15 min of reperfusion, and infarct size was measured after 120 min of reperfusion. IPC induced a threefold increase in Akt, Erk1/2, and p70S6K phosphorylation, at reperfusion. We found that inhibiting the PI3K-Akt (using LY294008) at reperfusion induced the phosphorylation of Erk1/2-p70S6K, and conversely, that inhibiting the MEK1/2-Erk1/2 pathway (using PD 98059) at reperfusion, induced the phosphorylation of Akt, suggesting 'cross-talk' between the two kinase pathways. However, this effect was not accompanied by a reduction in infarct size (43.1 +/- 7.2% with LY 294008 and 57.7 +/- 7.0% with PD 98059 vs. 46.3 +/- 5.8% in control; P = NS), suggesting that both the kinase cascades may need to be activated to mediate IPC-induced protection. IPC reduced the infarct-risk volume ratio to 17.8 +/- 2.3% from 46.3 +/- 5.8% in control (P < 0.01). Inhibiting p70S6K, a kinase situated downstream of both PI3K and Erk1/2, using rapamycin, abolished IPC-induced protection (46.0 +/- 7.7% with IPC+RAPA vs. 17.8 +/- 2.3% with IPC; P < 0.01).
CONCLUSIONS: We report that, the survival kinase cascades PI3K-Akt and MEK1/2-Erk1/2, which are recruited at the time of reperfusion in response to ischemic preconditioning, exhibit 'cross-talk' such that inhibiting one cascade activates the other and vice versa. Furthermore, at the time of reperfusion, these kinase cascades mediate IPC-induced protection, by acting in concert via p70S6K. Copyright 2004 European Society of Cardiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249188     DOI: 10.1016/j.cardiores.2004.04.011

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  57 in total

1.  Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore.

Authors:  Christopher C T Smith; Richard A Dixon; Abigail M Wynne; Louise Theodorou; Sang-Ging Ong; Sapna Subrayan; Sean M Davidson; Derek J Hausenloy; Derek M Yellon
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-23       Impact factor: 4.733

2.  Nerve growth factor activates aorta endothelial cells causing PI3K/Akt- and ERK-dependent migration.

Authors:  Ulrik L Rahbek; Steen Dissing; Camilla Thomassen; Anker J Hansen; Katerina Tritsaris
Journal:  Pflugers Arch       Date:  2005-05-28       Impact factor: 3.657

Review 3.  Mitochondrial therapeutics for cardioprotection.

Authors:  Raquel S Carreira; Pamela Lee; Roberta A Gottlieb
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 4.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

5.  Cx43 phosphorylation-mediated effects on ERK and Akt protect against ischemia reperfusion injury and alter the stability of the stress-inducible protein NDRG1.

Authors:  Joell L Solan; Lucrecia Márquez-Rosado; Paul D Lampe
Journal:  J Biol Chem       Date:  2019-06-12       Impact factor: 5.157

6.  Obesity--a risk factor or a RISK factor for myocardial infarction?

Authors:  G Heusch
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

7.  Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Bonnie H Hylander; Elizabeth A Repasky; Wen W Ma; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-03       Impact factor: 3.333

8.  Akt and Erk1/2 activate the ornithine decarboxylase/polyamine system in cardioprotective ischemic preconditioning in rats: the role of mitochondrial permeability transition pores.

Authors:  Hao Zhang; Guo Xue; Weihua Zhang; Lina Wang; Hong Li; Li Zhang; Fanghao Lu; Shuzhi Bai; Yan Lin; Yu Lou; Changqing Xu; Yajun Zhao
Journal:  Mol Cell Biochem       Date:  2014-01-24       Impact factor: 3.396

9.  Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells.

Authors:  Neil Kumar; Raffi Afeyan; Hyung-Do Kim; Douglas A Lauffenburger
Journal:  Mol Pharmacol       Date:  2008-03-18       Impact factor: 4.436

10.  The endogenous inhibitor of Akt, CTMP, is critical to ischemia-induced neuronal death.

Authors:  Takahiro Miyawaki; Dimitry Ofengeim; Kyung-Min Noh; Adrianna Latuszek-Barrantes; Brian A Hemmings; Antonia Follenzi; R Suzanne Zukin
Journal:  Nat Neurosci       Date:  2009-04-06       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.